Results 51 to 60 of about 51,886 (205)
Revista Brasileira de Hematologia e Hemoterapia, 2015 Myelodysplastic syndromes represent a group of heterogeneous hematopoietic neoplasms derived from an abnormal multipotent progenitor cell, characterized by a hyperproliferative bone marrow, dysplasia of the cellular hemopoietic elements and ineffective ...
Emmanouil Petrou +6 more
doaj +1 more source
Monosomal karyotype in MDS : explaining the poor prognosis? [PDF]
, 2013 Schanz, J., Tüchler, H., Solé, F., Mallo, M., Luño, E., Cervera, J., Grau, J., Hildebrandt, B., Slovak, M.L., Ohyashiki, K., Steidl, C., Fonatsch, C., Pfeilstöcker, M., Nösslinger, T., Valent, P., Giagounidis, A., Aul, C., Lübbert, M., Stauder, R ...
Luño Fernández, Elisa +3 more
core +1 more source
PTK2 and PTPN11 expression in myelodysplastic syndromes
Clinics, 2013 OBJECTIVE: The aim of this study was to evaluate the expression of protein tyrosine kinase 2 and protein tyrosine phosphatase non-receptor type 11, which respectively encode focal adhesion kinase protein and src homology 2 domain-containing protein ...
Mariana Lazarini +6 more
doaj +1 more source
A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers [PDF]
, 2016 The azanucleosides azacitidine and decitabine are currently used for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in patients not only eligible for intensive chemotherapy but are also being explored in other ...
Buschbeck, Marcus +5 more
core +2 more sources
Haematologica, 2017 Accumulating evidence implicates innate immune activation in the pathobiology of myelodysplastic syndromes. A key myeloid-related inflammatory protein, S100A9, serves as a Toll-like receptor ligand regulating tumor necrosis factor-α and interleukin-1β ...
Thomas Cluzeau +11 more
doaj +1 more source
A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. [PDF]
, 2019 BackgroundNovel, pragmatic, patient-centered strategies are needed to ensure fit-for-purpose patient-reported outcomes (PRO) instruments in clinical trial research for rare diseases such as myelodysplastic syndromes (MDS), acute myeloid leukemia (AML ...
Bejar, Rafael +9 more
core
Haematologica, 2012 Background There are limited reports of thrombosis among myelodysplastic syndrome patients exposed to erythropoiesis stimulating agents. It is not clear whether erythropoiesis stimulating agents are associated with an increased risk of thrombosis in ...
Sheila Weiss Smith +6 more
doaj +1 more source
Preleukemia: one name, many meanings. [PDF]
, 2017 Definition of preleukemia has evolved. It was first used to describe the myelodysplastic syndrome (MDS) with a propensity to progress to acute myeloid leukemia (AML). Individuals with germline mutations of either RUNX1, CEBPA, or GATA2 can also be called
Koeffler, HP, Leong, G
core
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: Results from the Spanish Registry [PDF]
, 2015 The benefit of azacitidine treatment in survival of high risk myelodysplastic syndromes (MDS) patients compared to conventional care treatment (CCT) has not been established outside clinical trials.
Amigo, M. L. +9 more
core +1 more source
Clinical and genetic predictors of prognosis in myelodysplastic syndromes
Haematologica, 2014 Myelodysplastic syndromes are a collection of clonal hematopoietic disorders with a wide range of clinical manifestations and eventual outcomes. Accurate prediction of a patient’s prognosis is useful to define the risk posed by the disease and which ...
Rafael Bejar
doaj +1 more source